Literature DB >> 6871557

Spinal interneurone depression by DS103-282.

D R Curtis, J D Leah, M J Peet.   

Abstract

The depressant effect of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiodiazole (DS103-282) on the polysynaptic excitation of interneurones in the cat spinal cord appears to be related to a postsynaptic reduction in the effectiveness of excitatory transmitters than to interference with their presynaptic release.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6871557      PMCID： PMC2044820          DOI： 10.1111/j.1476-5381.1983.tb10487.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  6 in total

1.  Pharmacology of glutamate and aspartate antagonists on cat spinal neurones.

Authors:  J Davies; J C Watkins
Journal:  Adv Biochem Psychopharmacol       Date:  1981

2.  Selective antagonism of amino acid-induced and synaptic excitation in the cat spinal cord.

Authors:  J Davies; J C Watkins
Journal:  J Physiol       Date:  1979-12       Impact factor: 5.182

3.  The use of low concentrations of divalent cations to demonstrate a role for N-methyl-D-aspartate receptors in synaptic transmission in amphibian spinal cord.

Authors:  P A Smith
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

4.  The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent.

Authors:  A C Sayers; H R Bürki; E Eichenberger
Journal:  Arzneimittelforschung       Date:  1980

5.  Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiodazole (DS103-282).

Authors:  J Davies
Journal:  Br J Pharmacol       Date:  1982-07       Impact factor: 8.739

6.  Selective effects of (-)-baclofen on spinal synaptic transmission in the cat.

Authors:  D R Curtis; D Lodge; J C Bornstein; M J Peet
Journal:  Exp Brain Res       Date:  1981       Impact factor: 1.972
  6 in total
  5 in total

Review 1.  Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

2.  Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).

Authors:  M Emre; G C Leslie; C Muir; N J Part; R Pokorny; R C Roberts
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

3.  The effect of centrally acting myorelaxants on NMDA receptor-mediated synaptic transmission in the immature rat spinal cord in vitro.

Authors:  R J Siarey; S K Long; R H Evans
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

4.  Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

Authors:  Herbert R Henney; Michael Chez
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

5.  Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord.

Authors:  J Davies; S E Johnston
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.